What happened
SK biopharmaceuticals disclosed a subsidiary's acquisition of SK Life Science Labs, Inc., worth US$34.6M.
For context, this deal is worth about 4.9% of the company's consolidated total assets.
| Target | SK Life Science Labs, Inc. |
|---|---|
| Deal value | US$34.6M |
| vs. company assets | 4.9% |
| Filed | 2026-03-06, Decision to acquire shares/equity in another company |
| Source | DART rcept 20260306800793 → open original filing |
Source: DART. Information only, not investment advice.